# Linezolid

## General description

| | |
|---|---|
| **INN** | Linezolid |
| **ATC codes** | J01XX08 |
| **Medicine type** | Chemical agent |
| **Antibiotic groups** | R RESERVE |
| **EML status history** | First added in 2015 (TRS 994) for Multi-drug resistant Mycobacterium tuberculosis<br>Changed in 2017 (TRS 1006) for Other specified bacterial diseases<br>Changed in 2019 (TRS 1021) for Vancomycin resistant Enterococcus<br>Changed in 2019 (TRS 1021) for Vancomycin resistant Staphylococcus aureus<br>Changed in 2019 (TRS 1021) for Methicillin resistant Staphylococcus aureus<br>Removed in 2019 (TRS 1021) for Other specified bacterial diseases |
| **Wikipedia** | Linezolid |
| **DrugBank** | Linezolid |

## Recommendations

**Section** Reserve group antibiotics

- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 400 mg tablet; 600 mg tablet
- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg

**Indications**

Other specified bacterial diseases

Vancomycin resistant Enterococcus

Vancomycin resistant Staphylococcus aureus

Methicillin resistant Staphylococcus aureus

**Section** Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg (scored)
- Oral > Solid > tablet: 600 mg

**Indications**

Multi-drug resistant Mycobacterium tuberculosis